Revenue Breakdown
Composition ()
No data
Revenue Streams
Myriad Genetics Inc (MYGN) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Hereditary Cancer, accounting for 45.2% of total sales, equivalent to $93.00M. Other significant revenue streams include Prenatal and Pharmacogenomics. Understanding this composition is critical for investors evaluating how MYGN navigates market cycles within the Medical Equipment, Supplies & Distribution industry.
Profitability & Margins
Evaluating the bottom line, Myriad Genetics Inc maintains a gross margin of 69.91%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -11.33%, while the net margin is -13.32%. These profitability ratios, combined with a Return on Equity (ROE) of -72.52%, provide a clear picture of how effectively MYGN converts its operational activities into shareholder value.
Comparative Benchmarking
In the context of the broader market, MYGN competes directly with industry leaders such as NPCE and OFIX. With a market capitalization of $520.60M, it holds a leading position in the sector. When comparing efficiency, MYGN's gross margin of 69.91% stands against NPCE's 77.39% and OFIX's 70.71%. Such benchmarking helps identify whether Myriad Genetics Inc is trading at a premium or discount relative to its financial performance.
